We started Minomic with a handful of people in 2007 convinced that biomarkers would be the next big thing in the diagnosis and treatment of human disease.
We are now on the cusp of bringing to market the MiCheck test, a new, non-invasive test for prostate cancer.
Using only a simple blood sample, the MiCheck test detects a protein that is present on cancer cells. It's shaping up to be more effective than existing tests and is almost ready for prime time.
Imagine collecting a sample and being able to tell whether the patient has prostate cancer.
You won't have to imagine for long.
Minomic International Founded
Showed antibody binding to prostate cancer cells
Received VC funding for commercialisation
First patient trial completed
Clinical validation studies
Regulatory framework and approvals